Table 3 In vivo and ex vivo 1H and 31P-MRS metabolic analysis of subcutaneous PC3 tumours and extracts following MK-2206 treatment

From: Metabolic biomarkers of response to the AKT inhibitor MK-2206 in pre-clinical models of human colorectal and prostate carcinoma

In vivo 1H and 31P-MRS of subcutaneous PC3 tumours

 

Vehicle-control

MK-2206

 

Pre

Post

Pre

Post

Corrected tCho/water ratio x 10−3 (n = 4 in each group)

3.63 ± 0.38

3.80 ± 0.64

3.26 ± 0.26

3.61 ± 0.17

 

P = 0.66

P = 0.31

PME/total P ratio (n = 5 in each group)

0.11 ± 0.01

0.12 ± 0.01

0.14 ± 0.01

0.17 ± 0.02

 

P = 0.50

**P = 0.02

Ex vivo 1H and 31P-MRS of subcutaneous PC3 tumour extracts

 

Vehicle-control

MK-2206

P

PE

1.03 ± 0.10

1.45 ± 0.13

0.03*

PC

1.53 ± 0.05

1.60 ± 0.20

0.75

GPE

0.44 ± 0.03

0.28 ± 0.04

0.02*

GPC

1.54 ± 0.14

0.94 ± 0.19

0.04*

Lactate

9.34 ± 0.85

7.14 ± 0.44

0.04*

Alanine

1.39 ± 0.13

1.49 ± 0.23

0.74

Glucose

0.45 ± 0.06

0.41 ± 0.03

0.48

Glutamine

1.20 ± 0.16

2.74 ± 0.48

0.02*

Glutamate

3.64 ± 0.41

3.02 ± 0.37

0.28

Glycine

1.21 ± 0.18

1.39 ± 0.16

0.48

Glutathione

1.53 ± 0.15

1.46 ± 0.12

0.74

Creatine

1.08 ± 0.09

1.38 ± 0.24

0.32

Phosphocreatine

0.39 ± 0.05

0.53 ± 0.05

0.08

ATP + ADP

0.84 ± 0.05

0.89 ± 0.07

0.63

  1. Data are expressed as µmol/g wet weight and presented as the mean  ±  sem, n  ≥  5 in each group. Two-tailed unpaired t test was used to compare MK2206-treated tumour extracts with vehicle-treated controls and *P  ≤  0.05 is considered significant. Aspartate was not detected.
  2. **Statistically significant when compared the pre-MK-2206 treatment values with post-treatment. Two-tailed paired t test was used and data are expressed as mean ± sem
  3. PME phosphomonoesters, total P total phorphorus signal
Back to article page